Retatrutide: Weight-Loss, Obesity & Triple-Receptor Research
This educational research page covers scientific questions about retatrutide, obesity, body-weight regulation, appetite, energy balance and GIP, GLP-1 and glucagon receptor signaling. It summarizes published and announced clinical research and does not provide treatment or self-use guidance.
What is retatrutide?
Retatrutide (LY3437943) is an investigational single-molecule agonist of the GIP, GLP-1 and glucagon receptors. It is being studied in obesity and related cardiometabolic conditions and remains investigational.
How does retatrutide work in research?
- GLP-1 receptor signaling: GLP-1 pathways are associated with satiety, reduced food intake and slower gastric emptying in established incretin research.
- GIP receptor signaling: GIP is an incretin pathway involved in nutrient-responsive insulin signaling and metabolic regulation.
- Glucagon receptor signaling: glucagon-receptor agonism is being investigated for effects on substrate use and energy expenditure alongside incretin signaling.
The scientific rationale for retatrutide is the combined activity of all three receptor pathways rather than a single GLP-1 mechanism.
Why is retatrutide studied in weight-loss and obesity research?
Retatrutide is being studied because GIP, GLP-1 and glucagon signaling can influence appetite, energy intake, glucose regulation, substrate utilization and energy balance. These mechanisms are under active clinical investigation.
What did the Phase 2 obesity study report?
In a published randomized Phase 2 study, participants with obesity showed dose-dependent body-weight reductions over 48 weeks. The highest-dose study arm reported a mean reduction of 24.2% from baseline at week 48. The result belongs to the specific investigational drug, protocol and study population.
What did Phase 3 TRIUMPH-1 report?
In May 2026, Eli Lilly announced positive topline results from the pivotal Phase 3 TRIUMPH-1 obesity trial. The highest-dose study arm reported an average body-weight reduction of 28.3% at 80 weeks. Lilly later announced positive Phase 3 results from TRIUMPH-2 and TRIUMPH-3.
Is retatrutide approved?
No. As of September 2026, retatrutide remains investigational and has not been approved by a regulatory agency. Lilly has stated that regulatory submissions are planned after the Phase 3 programme.
What safety findings have been reported?
In the published Phase 2 obesity study, gastrointestinal adverse events were the most frequently reported and were generally mild to moderate. Dose-dependent increases in heart rate were also reported. Safety findings from clinical trials apply to the specific investigational drug and study conditions.
Related scientific questions
- retatrutide and body-weight regulation
- retatrutide and obesity research
- GIP, GLP-1 and glucagon receptor signaling
- triple hormone receptor agonism
- appetite and satiety signaling
- energy expenditure and substrate utilization
- TRIUMPH-1 Phase 3 research
Primary sources
New England Journal of Medicine: Phase 2 obesity trial · ClinicalTrials.gov: TRIUMPH-1 · Eli Lilly: retatrutide programme status
Research information only. This page does not provide dosing, injection, treatment or self-administration guidance and does not establish the identity, safety, purity or efficacy of any separately supplied commercial material.